Anzeige
Mehr »
Login
Samstag, 28.11.2020 Börsentäglich über 12.000 News von 646 internationalen Medien
Lithium und Kupfer explodieren! Tesla warnte bereits vor Engpässen! Diese Kupfer-Aktie hat 194% Upside!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0F57T ISIN: JP3475350009 Ticker-Symbol: D4S 
Tradegate
27.11.20
18:49 Uhr
32,200 Euro
+1,010
+3,24 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
DAIICHI SANKYO CO LTD Chart 1 Jahr
5-Tage-Chart
DAIICHI SANKYO CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
31,13031,77012:37
31,30032,20027.11.

Aktuelle News zur DAIICHI SANKYO Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiTechnavio Research: Autologous Cell Therapy Market 2020-2024- Featuring Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., Among Others | Industry Analysis, Market Trends, Opportunities and Forecast 2024192The autologous cell therapy market is poised to grow by USD 1.97 bn during 2020-2024 progressing, at a CAGR of almost 22% during the forecast period. This press release features multimedia. View...
► Artikel lesen
DAIICHI SANKYO Aktie jetzt für 0€ handeln
18.11.Unterlagenschutz im Medizinrecht: Daiichi Sankyo sichert sich mit Bardehle Marktexklusivität für Blutdruckmedikament3
17.11.Daiichi Sankyo Company, Limited: Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCS353Longer follow-up research data for ENHERTU based on DESTINY-Breast01, including updated duration of response, progression-free survival, an 18-month landmark analysis of overall survival and longer-term...
► Artikel lesen
16.11.Daiichi Sankyo Europe GmbH: Pooled analyses show NILEMDO? significantly lowers cholesterol in different subgroups in Phase 3 data presented at AHA 2020275NILEMDO (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers Low-Density Lipoprotein Cholesterol (LDL-C) and can be combined with other treatments to help lower...
► Artikel lesen
12.11.Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization Dedicated to Patients with Cancer476Ken Keller Appointed as Head of the Oncology Business Unit Overseeing Global Oncology Strategy and U.S. and European Oncology Businesses Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo)...
► Artikel lesen
03.11.Daiichi Sankyo Co Ltd (DSKYF) CEO Sunao Manabe on Q2 2021 Results - Earnings Call Transcript7
02.11.Daiichi Sankyo Company, Limited: DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant Therapy359Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the initiation of DESTINY-Breast05, a global phase 3, head-to-head trial of ENHERTU (fam-trastuzumab deruxtecan-nxki)...
► Artikel lesen
30.10.Daiichi Sankyo Company, Limited 2020 Q2 - Results - Earnings Call Presentation7
30.10.Daiichi Sankyo Co. reports 1H results7
28.10.Enhertu picks up another win for AstraZeneca and Daiichi Sankyo, joining the priority review lane for gastric cancer9
28.10.Daiichi Sankyo: ENHERTU Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer316Only HER2 directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for previously treated patients in this setting Daiichi Sankyo Company, Limited...
► Artikel lesen
22.10.Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells348First-in-human phase 1 study to evaluate DS-1055 as a new type of immune intervention for patients with relapsed/refractory advanced or metastatic solid tumors Daiichi Sankyo combines novel...
► Artikel lesen
22.10.BioInvent receives €2 million milestone from Daiichi Sankyo407Payment related to development of GARP directed antibody into Phase I clinical trial LUND, Sweden, Oct. 22, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company")...
► Artikel lesen
19.10.Daiichi Sankyo (DSNKY) Presents At ESMO Follow-Up Meeting Hosted By Citi - Slideshow9
08.10.Liberum hikes target price for AstraZeneca on Daiichi Sankyo collaboration prospects15
08.10.Daiichi Sankyo Europe GmbH: NILEMDO significantly lowers cholesterol in people with familial hypercholesterolaemia shows new analysis presented at EAS 2020339NILEMDO(bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers cholesterol and can be combined with other treatments to help lower cholesterol even further1 Bempedoic...
► Artikel lesen
28.09.XFRA CAPITAL ADJUSTMENT INFORMATION - JP3475350009406CAPITAL ADJUSTMENT INFORMATION - 29.09.2020;Das Instrument D4S JP3475350009 DAIICHI SANKYO CO. LTD EQUITY wird cum Kapitalmassnahme gehandelt am 28.09.2020 und ex Kapitalmassnahme am 29.09.2020 The...
► Artikel lesen
25.09.Daiichi Sankyo: ENHERTU Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer530ENHERTU is the first and only HER2 directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for patients with previously treated HER2 positive advanced...
► Artikel lesen
18.09.Daiichi Sankyo Company, Limited: Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020429HER3 directed ADC demonstrates clinical activity in patients with EGFR-mutated metastatic or unresectable NSCLC previously treated with a tyrosine kinase inhibitor and platinum-based chemotherapy...
► Artikel lesen
16.09.Daiichi Sankyo, Thermo Fisher: Strategiedepot Vermögensstreuung521Auch in der abgelaufenen Woche hielten die Gewinnmitnahmen an den internationalen Aktienmärkten weiterhin an, obwohl sich die fundamentalen Nachrichten in keiner Weise weiter eintrübten. Der MSCI World...
► Artikel lesen
Seite:  Weiter >>
76 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2